Johnson and Johnson reports less abuse effects for Oros methylphenidate

The paediatrics division of McNeil-PPC, a Johnson & Johnson company, has published data indicating that the Oros formulation of attention deficit hyperactivity disorder (ADHD) drug methylphenidate results in fewer cases of abuse and abuse-related effects compared to other treatments for the condition.

Results from a pharmacokinetic study and a national review of visits to emergency departments in the US showed that the Oros formulation of the compound that gives an initial quantity of medication followed by an ascending gradual dose of the remaining medication could reduce the potential for abuse.

Data showed that abuse-related effects – drug-liking characteristics, were lower at comparable doses for the Oros methylphenidate formulation, while the compound was responsible for less emergency room visits than similar therapies.

John J Coleman, president of Prescription Drug Research Centre, said: “Although methylphenidate is proven to be an effective treatment for ADHD, some physicians may have concerns about the drug due to its abuse potential.”

He added that while the majority of patients take their medications sensibly, some abuse of stimulants does occur which is an ongoing concern for both doctors and the public.

In July 2006, Johnson & Johnson reported that its Janssen-Cilag subsidiary had reported strong sales of ADHD-drug Concerta over the second-quarter of the financial year.